AAA
PVLA

Affinity Asset Advisors’s Palvella Therapeutics PVLA Stock Holding History

Affinity Asset Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,837
Closed -$300K – 90
2023
Q1 		$300K Buy
+3,837
New +$444K 0.1% 69

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Affinity Asset Advisors's PVLA Position: Q2 2023 in Review

Affinity Asset Advisors sold out of Palvella Therapeutics (PVLA) in Q2 2023, closing a stake of 3,837 shares — an estimated $300K sold.

Affinity Asset Advisors first reported a position in PVLA in Q1 2023 and held it in 1 quarter. The position peaked at $300K in Q1 2023. 49 funds tracked by Wall St. Rank hold PVLA as of Q2 2023.

  • Affinity Asset Advisors reported no remaining Palvella Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Affinity Asset Advisors sold 3,837 Palvella Therapeutics shares in Q2 2023, an estimated $300K.
  • Affinity Asset Advisors first reported a position in Palvella Therapeutics in Q1 2023 and held it in 1 quarter.
  • Affinity Asset Advisors's Palvella Therapeutics position peaked at $300K in Q1 2023.
  • 49 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2023.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.